Personally I've always felt that ADAPT was the main driver for AHZ.
I've ignored the vaccine biz as the chances of success are slim.
On ADAPT alone I see AHZ moving towards $1 within 4 years.
it is the gold standard soft tissue patch, it has multiple potential applications within the human body.
Yes competition could appear but I haven't seen any yet. They raised capital to build their salesforce and capitalise on this opportunity. The numbers should start to reflect this in the next Qrtly.
Article on news.com.au, page-55
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |